CS First Boston Cuts Amgen to Neutral

Analyst Mark Augustine says he doesn't foresee compelling catalysts to drive sustainable price appreciation

CS First Boston downgraded Amgen (AMGN ) to neutral from outperform.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.